Stories
Symbiotec Pharmalab's Q1 Profit Plunges 53% to ₹14.1 Crore Amidst New Business Expenses.
- •Symbiotec Pharmalab's consolidated net profit for Q1 FY27 declined by 53% to ₹14.1 crore, down from ₹29.9 crore last year.
- •Consolidated revenue increased by 7.4% to ₹218.2 crore, but EBITDA and profit fell due to expenses from new businesses.
- •New business expenses, including ₹23 crore in operating expenses and ₹12 crore in depreciation, are currently not revenue-generating.
- •The API Business recorded an operating revenue of ₹215.3 crore and EBITDA of ₹65.8 crore, with API sales growing 6% year-on-year.
- •The company filed its first ANDA for Complex Injectables and secured long-term agreements in the Biotech-CDMO Business.
Key Questions Answered
Symbiotec Pharmalab's consolidated net profit dropped 53% year-on-year to ₹14.1 crore due to expenses related to new businesses, which included approximately ₹23 crore in operating expenses and ₹12 crore in depreciation without immediate revenue contributions.
Symbiotec estimated a total gross capex of approximately ₹1,666 crore by the end of FY27, with about 61% invested in new revenue-generating businesses. Additionally, the company's net debt decreased from ₹398 crore as of June 30, 2026, down to ₹326 crore following IPO proceeds by September 20, 2026.
Symbiotec filed its first ANDA for Dual Chamber Vial products in September 2026 for the US market and advanced work on a distribution licensing agreement. Meanwhile, its API business recorded a 6% year-on-year sales growth and maintained a gross margin of over 60% in Q1 FY27.
